Argenx NV, a prominent biopharmaceutical company, has made the strategic decision to terminate the late-stage Phase III UNITY study evaluating its subcutaneous formulation of efgartigimod alfa, Vyvgart Hytrulo (efgartigimod alfa, hyaluronidase-qvfc), for the treatment of Sjögren’s syndrome. This development marks a significant setback in the drug’s potential label expansion into this autoimmune indication, though the company maintains its commitment to exploring broader applications of its neonatal Fc receptor (FcRn) antagonist technology across various immunological disorders.
The abrupt halt to the UNITY trial, identified by its clinical trial identifier NCT06684847, was precipitated by a recommendation from the study’s independent Data Monitoring Committee (IDMC). Following a scheduled interim analysis, the IDMC concluded that the trial was unlikely to achieve its primary efficacy endpoint, leading to the premature discontinuation. While this news dashes hopes for an immediate Sjögren’s syndrome indication, argenx has emphasized that no new safety concerns were identified with Vyvgart Hytrulo during the study.
This outcome stands in stark contrast to earlier findings in a Phase II open-label study, the RHO+ trial (NCT06203457). In that study, patients treated with efgartigimod alfa demonstrated sustained low disease activity at the 72-week mark, offering a glimmer of promise for its therapeutic potential in autoimmune conditions. However, the results from the UNITY trial underscore the complexities and unique challenges associated with targeting Sjögren’s syndrome, a condition characterized by significant patient heterogeneity and a complex disease pathology.
The Complexities of Sjögren’s Syndrome and the Impact of the UNITY Trial Halt
Sjögren’s syndrome is a chronic autoimmune disease primarily affecting the exocrine glands, leading to debilitating symptoms such as severe dry eyes and dry mouth. Beyond these hallmark manifestations, the disease can also impact a wide range of other organs, including the joints, lungs, kidneys, brain, and skin, leading to systemic complications. Globally, it is estimated that around 300 million individuals are affected by this condition. Despite its prevalence and the significant impact on patients’ quality of life, there are currently no approved disease-modifying therapies (DMTs) specifically for Sjögren’s syndrome.
The current therapeutic landscape for Sjögren’s syndrome relies heavily on symptomatic management and the off-label use of existing treatments. Biologics such as rituximab (Rituxan), developed by Biogen and Roche, and belimumab (Benlysta), marketed by GSK, are sometimes employed for patients with severe disease activity or organ involvement. However, these therapies are not specifically indicated for Sjögren’s and may not address the underlying autoimmune mechanisms driving the disease. This unmet need has created a significant market opportunity for novel therapies that can effectively modify disease progression.
The discontinuation of the UNITY trial for Vyvgart Hytrulo in Sjögren’s syndrome represents a significant missed opportunity for argenx to address this critical unmet medical need. The drug’s mechanism of action as a neonatal Fc receptor (FcRn) antagonist is designed to reduce pathogenic autoantibodies, a key driver in many autoimmune diseases. The failure to demonstrate efficacy in the UNITY trial suggests that the specific profile of autoantibody-driven pathology in Sjögren’s syndrome may be less responsive to this approach, or that the trial design or patient population did not fully capture the drug’s potential benefits.
Chronology of Events and Strategic Realignments
The decision to terminate the UNITY trial was based on a comprehensive interim analysis conducted by the IDMC. This committee, comprised of independent experts, regularly reviews trial data to ensure patient safety and assess the study’s progress and likelihood of success. Their recommendation to discontinue the trial indicates a clear signal that the predetermined statistical hurdles for efficacy were unlikely to be met.
Prior to this development, argenx had been actively pursuing label expansion for Vyvgart Hytrulo across a spectrum of immunological indications. The drug is already approved by the U.S. Food and Drug Administration (FDA) for the treatment of neurological disorders, specifically generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company’s broader pipeline strategy involves investigating efgartigimod alfa and its subcutaneous formulation, Vyvgart Hytrulo, in various rheumatological diseases, including systemic sclerosis, endocrinological conditions such as Graves’ disease, and hematological disorders like immune thrombocytopenia.
The disappointing outcome in the UNITY trial necessitates a strategic reassessment of argenx’s approach to Sjögren’s syndrome. The company has stated its intention to thoroughly analyze the data generated from the UNITY study. This analysis is expected to provide valuable insights into the disease’s complex pathophysiology and potentially inform future research efforts in the Sjögren’s space, even if not directly involving Vyvgart Hytrulo.
Supporting Data and the Landscape of Emerging Sjögren’s Therapies
While the UNITY trial for Vyvgart Hytrulo has been discontinued, the broader landscape for Sjögren’s syndrome treatment is on the cusp of significant advancements. Several promising therapies are currently in late-stage development, offering hope for a breakthrough in addressing the long-standing lack of approved disease-modifying treatments.
One notable contender is Novartis’s ianalumab. This therapy has already achieved a dual Phase III success through its NEPTUNUS program (NCT05350072; NCT05349214). The positive results from these trials have prompted the Swiss pharmaceutical giant to prepare for potential regulatory submissions in the United States for Sjögren’s syndrome. Ianalumab’s success suggests a different therapeutic avenue may be more effective in targeting the disease mechanisms.
Novartis is not the sole player in this competitive arena. Amgen is also advancing its investigational therapy, dazodalibep, through Phase III trials. The OASIZ 301 trial (NCT06104124) recently reported a positive outcome, further bolstering the pipeline of potential new treatments for Sjögren’s.
In addition, Vor Bio and RemeGen have reported encouraging results for their candidate, telitacicept, from a late-stage study conducted in China (NCT05673993). The drug’s global commercial potential will ultimately depend on its ability to demonstrate efficacy in the ongoing U.S.-based Phase III program. These ongoing trials highlight a burgeoning era for Sjögren’s syndrome therapeutics, with multiple companies vying to bring the first truly disease-modifying treatments to patients.
Official Responses and Future Outlook
Luc Truyen, Chief Medical Officer at argenx, acknowledged the complexities of Sjögren’s syndrome, describing it as "one of the most heterogeneous and complicated diseases" within the immunology space. This statement underscores the inherent challenges in developing effective treatments for conditions with such diverse presentations and underlying mechanisms. While the company expressed disappointment regarding the UNITY trial outcome, its commitment to advancing its FcRn antagonist technology across other immunological indications remains unwavering.
The discontinuation of the UNITY trial does not diminish argenx’s broader ambitions in immunology. The company continues to actively pursue label expansion for Vyvgart and Vyvgart Hytrulo in a range of autoimmune and inflammatory conditions. The insights gained from the UNITY study, even in its failure to meet its primary endpoint, are expected to contribute to argenx’s understanding of disease biology and inform future drug development strategies. This dedication to scientific inquiry and patient-centric innovation is a hallmark of argenx’s approach.
Implications for the Pharmaceutical Industry and Patients
The outcome of the UNITY trial has several significant implications for the pharmaceutical industry and, most importantly, for patients living with Sjögren’s syndrome.
For the pharmaceutical industry, the trial’s discontinuation serves as a reminder of the inherent risks and uncertainties associated with drug development, particularly in complex autoimmune diseases. It highlights the critical need for robust clinical trial design, careful patient selection, and a deep understanding of disease heterogeneity. The success of competitors like Novartis and Amgen in their Sjögren’s trials suggests that alternative therapeutic targets or approaches may prove more fruitful.
For patients with Sjögren’s syndrome, the halt of the UNITY trial is a blow to the hope of a new treatment option becoming available in the near future. However, the simultaneous progress of other investigational therapies offers a strong reason for optimism. The influx of potential new treatments in late-stage development signals a potential paradigm shift in how Sjögren’s syndrome is managed, moving beyond symptomatic relief towards disease modification. The coming years will be crucial in determining which of these emerging therapies will ultimately gain regulatory approval and offer a tangible improvement in the lives of millions affected by this debilitating condition. Argenx’s continued focus on other immunological indications also means that their expertise in FcRn antagonism may still yield significant benefits for patients with other autoimmune diseases.
About the Author
